PLK1 and glioblastoma: Velpurisina and Rai (2019) created a polymeric nanoparticle composed of poly (lactic-co-glycolic) acid and polyethylene glycol for GBM treatment, co-delivering gefitinib, an EGFR inhibitor, and GSK461364A, a Polo-like kinase-1 (PLK-1) inhibitor.